The introduction of efficacious new hepatitis C virus (HCV) treatments galvanized the World
Health Organization to define ambitious targets for eliminating HCV as a public health threat …

Antiviral drugs such as Remdesivir (Veklury), Nirmatrelvir with Ritonavir (Paxlovid),
Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus …

Background Whether sofosbuvir is suitable for hepatitis C virus (HCV) infected patients with
severe renal impairment is inconclusive. This systematic review aims to evaluate the safety …

Background There is a medical need for highly effective, safe, and well tolerated treatments
for patients infected with hepatitis C virus (HCV) with severe renal impairment. We …

This article is published as part of a supplement supported by Kidney Disease: Improving
Global Outcomes (KDIGO). The development and publication of this guideline were …

Aim Glecaprevir (GLE) and pibrentasvir (PIB) are new direct‐acting antiviral agents (DAAs)
with pangenotypic inhibitors that respectively target the hepatitis C virus (HCV) NS3/4 …

Chronic hepatitis C virus (HCV) infection is common among patients with chronic kidney
disease (CKD) and those on hemodialysis due to nosocomial infections and past blood …

Abstract Background and Aim Many of the treatment regimens available for hepatitis C
include sofosbuvir. Unfortunately, sofosbuvir has not been recommended for use in patients …

Abstract Background & Aims There is emerging data on the use of Sofosbuvir‐based directly
acting antiviral (DAA) drug regimens in chronic hepatitis C (CHC) patients with end‐stage …

ABSTRACT Introduction Hepatitis C virus (HCV) infection is associated with an increased
incidence and progression of chronic kidney disease (CKD), as well as higher mortality in …